ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, announced today that it has successfully completed the placebo-controlled phase I study involving 24 healthy volunteers of its lead compound IPP-201101 for Lupus, a chronic, life-threatening autoimmune disease.
